Outcome of Board Meeting of the Company held on May 18, 2026
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Strides Pharma Science reported consolidated revenue of Rs. 48,586.83 million for FY2026, up 6.4% from Rs. 45,653.35 million in FY2025. Profit after tax from continuing operations grew significantly to Rs. 5,745.20 million, a 40.3% increase over the prior year's Rs. 4,094.05 million. The Board approved a final dividend of Rs. 5 per equity share (50% payout). B S R & Co. LLP issued an unmodified (clean) audit opinion with no qualifications. The demerger of the CDMO and Soft Gelatin business into OneSource Specialty Pharma was completed in November 2024, and the results are presented separately as discontinued operations. Exceptional items for the year included product recall charges (Rs. 228.79 million), partially offset by other items.
Strong PAT growth of 40% is positive for shareholders, and the clean audit opinion provides confidence in financial reporting integrity. The demerger has simplified the group's business structure into a focused pharmaceutical operation.